James Emmett Herndon II

Journal article Neurooncol Pract · June 2026 BACKGROUND: Stereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective local control with fewer neurocognitive side effects. However, distinguishing radiation necrosis (RN) from local recurrence (LR) is chall ... Full text Link to item Cite

Inpatient and Outpatient Palliative Care Utilization Rates of Patients With Spine Metastases.

Journal article Spine (Phila Pa 1976) · May 1, 2026 STUDY DESIGN: Retrospective review. OBJECTIVE: Specialty palliative care (PC) can be instrumental in improving patient quality of life for patients with spine metastasis. It is important to identify disparities in access to PC to ensure that equitable care ... Full text Open Access Link to item Cite

Perioperative Depressive Symptoms in Surgical Cancer Patients: a Systematic Review and Meta-analysis.

Journal article Ann Surg Oncol · March 2026 BACKGROUND: Patients with cancer requiring surgery are at increased risk for depressive symptoms. However, prevalence and severity during the perioperative period are poorly characterized. This study systematically reviewed the perioperative prevalence of ... Full text Link to item Cite

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

Journal article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Open Access Link to item Cite

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Journal article Cancer · November 1, 2025 BACKGROUND: Treatment options for patients with advanced non-small cell lung cancer (NSCLC) with disease progression following immune checkpoint inhibitor (ICI) and platinum-based chemotherapy are limited. GT103 is a fully human immunoglobulin G3 monoclona ... Full text Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.

Journal article Sci Rep · October 23, 2025 Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically approved PCSK9 in ... Full text Open Access Link to item Cite

Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample.

Journal article Am J Hosp Palliat Care · September 2025 BackgroundPrimary brain tumors (PBTs) pose a significant health challenge, affecting patients and their caregivers. While early integration of palliative care (PC) has shown benefits in advanced cancer, its integration for PBT patients, particularly gliobl ... Full text Open Access Link to item Cite

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.

Journal article Nat Cancer · September 2025 The human cytomegalovirus (CMV) antigen pp65 is expressed in high-grade glioma (HGG) and medulloblastoma but not in the adjacent brain. This single-arm phase 1 trial ( NCT03299309 ) assessed the safety and immunogenicity of a peptide vaccine (PEP-CMV) targ ... Full text Open Access Link to item Cite

Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting.

Journal article Neurooncol Pract · August 2025 BACKGROUND: Nausea and vomiting remain feared cancer treatment-related side effects. Antiemetic guideline trials exclude malignant glioma patients. In patients receiving radiation with concurrent temozolomide, chemoradiation-induced nausea; vomiting (cRINV ... Full text Open Access Link to item Cite

Intraoperative brain tumor classification via laser-induced fluorescence spectroscopy and machine learning.

Journal article J Neurosurg · August 1, 2025 OBJECTIVE: To optimize neurosurgical tumor resection, tissue types and borders must be appropriately identified. Authors of this study established the use of a nondestructive laser-based endogenous fluorescence spectroscopy device, "TumorID," to almost imm ... Full text Open Access Link to item Cite

Disparities in clinical trial enrollment related to laser interstitial thermal therapy for central nervous system metastases.

Journal article Neurosurg Rev · July 22, 2025 OBJECTIVE: Laser interstitial thermal therapy (LITT) is a minimally invasive option for the management of a variety of intracranial pathologies, including radiographically progressive tumor following stereotactic radiosurgery. Although LITT has been increa ... Full text Link to item Cite

Financial toxicity of oral chemotherapy in patients with primary brain tumors.

Journal article Neurooncol Pract · February 2025 BACKGROUND: Cancer treatment costs continue to rise with the development of new agents. Financial toxicity is defined as the quantifiable costs associated with cancer and cancer treatment in addition to the patient's associated distress. This study's ratio ... Full text Open Access Link to item Cite

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Journal article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item Cite

Validation of the graded prognostic assessment and recursive partitioning analysis as prognostic tools using a modern cohort of patients with brain metastases.

Journal article Neurooncol Pract · December 2024 BACKGROUND: Prognostic indices for patients with brain metastases (BM) are needed to individualize treatment and stratify clinical trials. Two frequently used tools to estimate survival in patients with BM are the recursive partitioning analysis (RPA) and ... Full text Open Access Link to item Cite

Machine Learning-Driven Phenogrouping and Cardiorespiratory Fitness Response in Metastatic Breast Cancer.

Journal article JCO Clin Cancer Inform · September 2024 PURPOSE: The magnitude of cardiorespiratory fitness (CRF) impairment during anticancer treatment and CRF response to aerobic exercise training (AT) are highly variable. The aim of this ancillary analysis was to leverage machine learning approaches to ident ... Full text Link to item Cite

Automated segmentation of ablated lesions using deep convolutional neural networks: A basis for response assessment following laser interstitial thermal therapy.

Journal article Neuro Oncol · June 3, 2024 BACKGROUND: Laser interstitial thermal therapy (LITT) of intracranial tumors or radiation necrosis enables tissue diagnosis, cytoreduction, and rapid return to systemic therapies. Ablated tissue remains in situ, resulting in characteristic post-LITT edema ... Full text Link to item Cite

Variation in Oral Board Examination Accommodations Among Specialties.

Journal article JAMA Netw Open · May 1, 2024 IMPORTANCE: Board certification can have broad implications for candidates' career trajectories, and prior research has found sociodemographic disparities in pass rates. Barriers in the format and administration of the oral board examinations may dispropor ... Full text Open Access Link to item Cite

A blinded study using laser induced endogenous fluorescence spectroscopy to differentiate ex vivo spine tumor, healthy muscle, and healthy bone.

Journal article Sci Rep · January 22, 2024 Ten patients undergoing surgical resection for spinal tumors were selected. Samples of tumor, muscle, and bone were resected, de-identified by the treating surgeon, and then scanned with the TumorID technology ex vivo. This study investigates whether Tumor ... Full text Open Access Link to item Cite

Combination checkpoint blockade and laser interstitial thermal therapy in radiographically progressive non-small cell lung cancer brain metastases.

Journal article Neurooncol Adv · 2024 BACKGROUND: Laser interstitial thermal therapy (LITT) is a minimally invasive surgical treatment being employed frequently for radiographically progressive brain metastases. Considerable interest exists in combining LITT-mediated in situ vaccination to lic ... Full text Link to item Cite

Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.

Journal article Eur Heart J · December 7, 2023 AIMS: The most appropriate timing of exercise therapy to improve cardiorespiratory fitness (CRF) among patients initiating chemotherapy is not known. The effects of exercise therapy administered during, following, or during and following chemotherapy were ... Full text Link to item Cite

Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.

Journal article Lung Cancer · December 2023 OBJECTIVES: To assess the prevalence of lung cancer in Lung-RADS category 4 patients, and to elucidate if clinical or imaging features help differentiate benign lesions from lung cancer. MATERIALS/METHODS: A retrospective review of lung cancer screening (L ... Full text Link to item Cite

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Journal article Lancet Child Adolesc Health · July 2023 BACKGROUND: Outcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric ... Full text Link to item Cite

CD155 is a putative therapeutic target in medulloblastoma.

Journal article Clin Transl Oncol · March 2023 BACKGROUND: Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of ... Full text Link to item Cite

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Journal article Sci Transl Med · February 8, 2023 D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesized tha ... Full text Link to item Cite

Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery.

Journal article Adv Radiat Oncol · 2023 PURPOSE: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-S ... Full text Link to item Cite

ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination.

Journal article Neurooncol Adv · 2023 BACKGROUND: Medulloblastoma is the most common malignant pediatric brain tumor, and leptomeningeal dissemination (LMD) of medulloblastoma both portends a poorer prognosis at diagnosis and is incurable at recurrence. The biological mechanisms underlying LMD ... Full text Link to item Cite

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

Journal article Support Care Cancer · April 2022 PURPOSE: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of ... Full text Link to item Cite

Availability and role of clinical pharmacists in ambulatory neuro-oncology.

Journal article Neurooncol Pract · February 2022 BACKGROUND: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambu ... Full text Link to item Cite

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Journal article Clin Cancer Res · January 1, 2022 Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action-based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial ... Full text Link to item Cite

Prognostic significance of a complement factor H autoantibody in early stage NSCLC.

Journal article Cancer Biomark · 2022 BACKGROUND: Biomarkers that predict which patients with early stage NSCLC will develop recurrent disease would be of clinical value. We previously discovered that an autoantibody to a complement regulatory protein, complement factor H (CFH), is associated ... Full text Open Access Link to item Cite

Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.

Journal article Adv Radiat Oncol · 2022 PURPOSE: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These pat ... Full text Link to item Cite

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.

Journal article Front Oncol · 2022 BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). This study explores the impact of timing and type of systemic thera ... Full text Link to item Cite

Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases.

Journal article Neurooncol Adv · 2022 BACKGROUND: Improved survival for patients with brain metastases has been accompanied by a rise in tumor recurrence after stereotactic radiotherapy (SRT). Laser interstitial thermal therapy (LITT) has emerged as an effective treatment for SRT failures as a ... Full text Link to item Cite

Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial.

Journal article J Cachexia Sarcopenia Muscle · December 2021 BACKGROUND: Poor cardiorespiratory fitness (CRF) is a cardinal feature of post-treatment primary lung cancer. The most effective exercise therapy regimen to improve CRF has not been determined. METHODS: In this parallel-group factorial randomized controlle ... Full text Link to item Cite

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.

Journal article CNS Oncol · September 1, 2021 Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for ... Full text Open Access Link to item Cite

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

Journal article Neurooncol Pract · June 2021 BACKGROUND: Spirituality can impact patients' attitudes and decisions about treatment and end-of-life care when coping with cancer. Previous studies documented health-related quality of life (HRQoL) and spiritual well-being (SWB) as positively correlated w ... Full text Link to item Cite

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.

Journal article NPJ Vaccines · January 18, 2021 Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers ex ... Full text Open Access Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.

Journal article Front Oncol · 2021 OBJECTIVES: Standard 6-week and hypofractionated 3-week courses of adjuvant radiation therapy (RT) are both options for older patients with glioblastoma (GBM), but deciding the optimal regimen can be challenging. This analysis explores clinical factors ass ... Full text Open Access Link to item Cite

Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.

Journal article Adv Radiat Oncol · 2021 PURPOSE: To examine the effectiveness and safety of single-isocenter multitarget stereotactic radiosurgery using a volume-adapted dosing strategy in patients with 4 to 10 brain metastases. METHODS AND MATERIALS: Adult patients with 4 to 10 brain metastases ... Full text Link to item Cite

Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".

Journal article Support Care Cancer · December 2020 Full text Link to item Cite

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.

Journal article Clin Cancer Res · October 15, 2020 Despite standard of care for glioblastoma, including gross total resection, high-dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this ... Full text Link to item Cite

ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Journal article Neurosurgery · May 1, 2020 BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). OB ... Full text Link to item Cite

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Journal article Support Care Cancer · May 2020 PURPOSE: CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has r ... Full text Link to item Cite

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.

Journal article J Neurooncol · April 2020 PURPOSE: Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin's lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~ 3% of all primary central nervous ... Full text Open Access Link to item Cite

Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.

Journal article Circulation · February 18, 2020 BACKGROUND: Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise pr ... Full text Link to item Cite

Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma.

Journal article J Adv Pract Oncol · 2020 Patients with glioblastoma have poor overall survival and experience significant burden from neurologic decline and adverse treatment effects. Despite the well-known benefits of early palliative care integration with oncology care, utilization of palliativ ... Full text Open Access Link to item Cite

Second primary cancers in long-term survivors of glioblastoma.

Journal article Neurooncol Pract · September 2019 BACKGROUND: Overall survival (OS) in glioblastoma (GBM) is poor at an average of 14 to 18 months, and long-term survivors (LTS) of GBM are rare. LTS of GBM, defined as surviving >5 years postdiagnosis, represent only 2% to 10% of all GBM patients. LTS of c ... Full text Link to item Cite

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

Journal article Complement Ther Clin Pract · August 2019 BACKGROUND AND PURPOSE: Little is known about complementary and integrative health intervention usage in the primary brain tumor population. We aimed to identify the percentage of patients using these practices and explore the impact on quality of life. MA ... Full text Link to item Cite

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Journal article Cancer Res · July 1, 2019 Homozygous deletion of methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic ... Full text Link to item Cite

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Journal article Health Sci Rep · April 2019 BACKGROUND AND AIMS: This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting. METHODS: Adult pat ... Full text Link to item Cite

Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Journal article Nat Med · March 2019 In the version of this article originally published, the figure callout in this sentence was incorrect: "Furthermore, in S1P1-KI mice themselves, whereas PD-1 blockade was ineffectual as monotherapy, the effects of 4-1BB agonism and checkpoint blockade pro ... Full text Link to item Cite

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Journal article Clin Cancer Res · January 1, 2019 PURPOSE: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4+FoxP3+ regulatory T cells (Tregs). Although lymphodepletion is commonly used to deplete ... Full text Link to item Cite

MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.

Journal article J Neuropathol Exp Neurol · January 1, 2019 Glioma therapeutic resistance to alkylating chemotherapy is mediated via O6-methylguanine-DNA methyltransferase (MGMT). We hypothesized that a CD45/HAM56/MGMT double-stained cocktail would improve MGMT discrimination in tumor cells versus inflammatory and ... Full text Link to item Cite

Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.

Journal article Semin Oncol Nurs · December 2018 OBJECTIVES: To describe the adaptability to the patterns in symptoms and quality of life (QoL) during 6 months post low-grade glioma diagnosis by valid and reliable tools; to identify through qualitative interviews patient/provider adaptive techniques and ... Full text Link to item Cite

Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.

Journal article J Clin Neurosci · October 2018 Convection Enhanced Delivery (CED) infuses therapeutic agents directly into the intracranial area continuously under pressure. The convection improves the distribution of therapeutics such as those aimed at brain tumors. Although CED successfully delivers ... Full text Link to item Cite

The clinical importance of medulloblastoma extent of resection: a systematic review.

Journal article J Neurooncol · September 2018 BACKGROUND: Although the majority of current medulloblastoma adjuvant therapy protocols treat patients with ≥ 1.5 cm2 residual tumor as high risk with increased craniospinal irradiation, the true prognostic significance of extent of resection (EOR) in medu ... Full text Link to item Cite

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Journal article Nat Med · September 2018 T cell dysfunction contributes to tumor immune escape in patients with cancer and is particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is characteristic, yet often attributed to treatment. We reveal that even treatment- ... Full text Link to item Cite

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Journal article Oncologist · August 2018 LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall surviva ... Full text Link to item Cite

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Journal article Clin Cancer Res · August 1, 2018 Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.

Journal article Cancer · June 15, 2018 BACKGROUND: The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety of aerobic training in metastatic breast cancer. METHODS: Sixty-five women (age, 21-80 years) wi ... Full text Link to item Cite

Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.

Journal article Med Sci Sports Exerc · June 2018 PURPOSE: The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS: Using a retrospective analysis of a randomized trial ... Full text Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Journal article Neurology · April 10, 2018 150 ... Link to item Cite

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Journal article J Neurooncol · April 2018 Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibi ... Full text Link to item Cite

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Journal article Cancer Res · January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets. A recen ... Full text Link to item Cite

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Journal article Oncoimmunology · 2018 Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In orde ... Full text Open Access Link to item Cite

Adjunctive perampanel for glioma-associated epilepsy.

Journal article Epilepsy Behav Case Rep · 2018 Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted ... Full text Link to item Cite

Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases

Journal article Chinese Neurosurgical Journal · October 3, 2017 Background: While the optimal combination of whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgical resection in the treatment of brain metastases, is controversial, the addition of SRS to surgical resction of solitary metastasis may ... Full text Cite

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Journal article Neuro Oncol · October 1, 2017 BACKGROUND: Stereotactic radiosurgery (SRS) offers excellent local control for brain metastases (BM) with low rates of toxicity. Radiation necrosis (RN) may occur after treatment and is challenging to distinguish from local recurrence (LR). We evaluated en ... Full text Link to item Cite

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Journal article J Neurooncol · September 2017 Primary brain tumor patients experience high levels of distress. The purpose of this cross-sectional, retrospective study is to evaluate the level and different sources of psychosocial distress and how these pertain to health-related quality of life (HRQoL ... Full text Link to item Cite

Rethinking Autoantibody Signature Panels for Cancer Diagnosis.

Journal article J Thorac Oncol · June 2017 INTRODUCTION: Most pulmonary nodules found on imaging studies are indeterminate, but because of the concern for lung cancer, all patients require further evaluation with resultant radiation risk, significant cost, and delays in diagnosis. We hypothesized t ... Full text Link to item Cite

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Journal article Clin Cancer Res · April 15, 2017 Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can e ... Full text Link to item Cite

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Journal article Cancer Invest · January 2, 2017 The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who unde ... Full text Link to item Cite

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Journal article Ther Clin Risk Manag · 2017 PURPOSE: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron ( ... Full text Link to item Cite

Single fraction stereotactic radiosurgery for multiple brain metastases.

Journal article Adv Radiat Oncol · 2017 INTRODUCTION: Due to the neurocognitive side effects of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) is being used with increasing frequency. The use of SRS is expanding for patients with multiple (>4) brain metastases (BM). This s ... Full text Open Access Link to item Cite

Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Journal article CNS Oncol · October 2016 All cancer patients experience distress from the diagnosis, the effects of the disease or the treatment. Clinically significant distress decreases overall quality of life and the recognition of distress with prompt intervention is essential. The National C ... Full text Link to item Cite

Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.

Journal article Environ Mol Mutagen · June 2016 Combinations of radiotherapy (RT) and chemotherapy have shown efficacy toward brain tumors. However, therapy-induced oxidative stress can damage normal brain tissue, resulting in both progressive neurocognitive loss and diminished quality of life. We have ... Full text Link to item Cite

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Journal article Cancer Immunol Immunother · February 2016 Regulatory B cells that secrete IL-10 (IL-10(+) Bregs) represent a suppressive subset of the B cell compartment with prominent anti-inflammatory capacity, capable of suppressing cellular and humoral responses to cancer and vaccines. B lymphocyte stimulator ... Full text Link to item Cite

Insomnia and its associations in patients with recurrent glial neoplasms.

Journal article Springerplus · 2016 BACKGROUND: Patient with neurological disorders and cancer can develop sleep disturbance, in particular insomnia. Etiology of insomnia is multi-factorial in primary brain tumour patients with possible causes including corticosteroids, psychoactive medicati ... Full text Open Access Link to item Cite

X-Ray Psoralen Activated Cancer Therapy (X-PACT).

Journal article PLoS One · 2016 This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photo ... Full text Open Access Link to item Cite

Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity.

Journal article J Pain Symptom Manage · October 2015 CONTEXT: Measurement of dyspnea is important for clinical care and research. OBJECTIVES: To characterize the relationship between the 0-10 Numerical Rating Scale (NRS) and four-level categorical Verbal Descriptor Scale (VDS) for dyspnea assessment. METHODS ... Full text Link to item Cite

Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".

Journal article J Thorac Oncol · October 2015 Full text Open Access Link to item Cite

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Journal article Oncologist · July 2015 LESSONS LEARNED: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debu ... Full text Link to item Cite

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Journal article J Thorac Oncol · June 2015 INTRODUCTION: Patients with stage I non-small-cell lung cancer (NSCLC) have a wide variation in outcomes, most likely because there are undetected metastases at presentation. We retrospectively reviewed patients with early stage lung cancer to determine if ... Full text Link to item Cite

Prognostic marker analysis in pediatric intracranial ependymomas.

Journal article J Neurooncol · April 2015 Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detecti ... Full text Link to item Cite

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Journal article Nature · March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vacci ... Full text Open Access Link to item Cite

Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.

Journal article Clin Lymphoma Myeloma Leuk · February 2015 BACKGROUND: The safety and feasibility of the symptom-limited cardiopulmonary exercise test (CPET) and the 6-minute walk test (6MWT) has not been rigorously tested in patients with multiple myeloma (MM) after high-dose chemotherapy with autologous stem cel ... Full text Link to item Cite

Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.

Journal article Mol Cancer Ther · January 2015 Cranial irradiation is a standard therapy for primary and metastatic brain tumors. A major drawback of radiotherapy (RT), however, is long-term cognitive loss that affects quality of life. Radiation-induced oxidative stress in normal brain tissue is though ... Full text Link to item Cite

Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.

Journal article Int J Radiat Oncol Biol Phys · January 1, 2015 PURPOSE: To identify an optimal margin about the gross target volume (GTV) for stereotactic radiosurgery (SRS) of brain metastases, minimizing toxicity and local recurrence. METHODS AND MATERIALS: Adult patients with 1 to 3 brain metastases less than 4 cm ... Full text Link to item Cite

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Journal article J Neurooncol · December 2014 Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and support ... Full text Link to item Cite

Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Journal article Bone Marrow Transplant · October 2014 The feasibility of symptom-limited cardiopulmonary exercise testing (CPET) prior to allo-SCT was assessed in addition to the prognostic value of CPET-derived measures. CPET was performed prospectively on 21 patients with hematologic malignancies, with asse ... Full text Link to item Cite

Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients.

Journal article Oncologist · September 2014 BACKGROUND: The purpose of this study was to investigate the extent of pre-exercise participation ("preparticipation") health screening in a heterogeneous cohort of adult cancer patients. METHODS: Patients (n = 413) with histologically confirmed solid or h ... Full text Link to item Cite

A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.

Journal article J Neurosurg · September 2014 OBJECT: Robust methodology that allows objective, automated, and observer-independent measurements of brain tumor volume, especially after resection, is lacking. Thus, determination of tumor response and progression in neurooncology is unreliable. The obje ... Full text Link to item Cite

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.

Journal article Support Care Cancer · July 2014 PURPOSE: A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting ... Full text Link to item Cite

Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.

Journal article Neuro Oncol · July 2014 PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tum ... Full text Link to item Cite

Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Journal article Neuro Oncol · July 2014 Malignant cells must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the telomere binding proteins alpha thalassemia/mental retardation syndrome ... Full text Link to item Cite

Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.

Journal article Appl Physiol Nutr Metab · June 2014 The purpose of this study was to examine the relationship between self-reported exercise behavior, cardiorespiratory fitness (CRF), and cognitive function in early breast cancer patients. Thirty-seven breast cancer patients following completion of chemothe ... Full text Link to item Cite

Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.

Journal article Eur Urol · May 2014 UNLABELLED: Erectile dysfunction (ED) is a major adverse effect of radical prostatectomy (RP). We conducted a randomized controlled trial to examine the efficacy of aerobic training (AT) compared with usual care (UC) on ED prevalence in 50 men (n=25 per gr ... Full text Link to item Cite

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Journal article Oncotarget · March 30, 2014 Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or o ... Full text Open Access Link to item Cite

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Journal article Clin Cancer Res · February 15, 2014 PURPOSE: Chimeric antigen receptor (CAR) transduced T cells represent a promising immune therapy that has been shown to successfully treat cancers in mice and humans. However, CARs targeting antigens expressed in both tumors and normal tissues have led to ... Full text Link to item Cite

SEER insights.

Journal article J Neurosurg · February 2014 Full text Link to item Cite

Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.

Journal article Breast Cancer Res Treat · February 2014 Conventional resting left ventricular ejection fraction (LVEF) assessments have limitations for detecting doxorubicin (DOX)-related cardiac dysfunction. Novel resting echocardiographic parameters, including 3-dimensional echocardiography (3DE) and global l ... Full text Link to item Cite

Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer.

Journal article Respirology · January 2014 BACKGROUND AND OBJECTIVE: In this era of increasing options for treatment of 'surgical' lung cancer patients, preoperative physiologic assessment of accurate patient selection is becoming more important. The variability in an objective measure of cardiores ... Full text Link to item Cite

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Journal article PLoS One · 2014 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal bra ... Full text Open Access Link to item Cite

Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.

Journal article Acta Oncol · January 2014 BACKGROUND: To evaluate the safety and efficacy of moderate-to-high intensity aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. METHODS: Twenty patients with stage IIB-IIIC operable breast cancer were randomly assigned to recei ... Full text Link to item Cite

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Journal article J Clin Neurosci · January 2014 Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of malignant disease. Here, we demonstrate that intracerebral injection with a human, epidermal growth factor receptor variant III (EGFRvIII)-specific, third generation ... Full text Link to item Cite

Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.

Journal article J Thorac Oncol · December 2013 INTRODUCTION: To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non-small-cell lung cancer (NSCLC). METHODS: One hun ... Full text Link to item Cite

ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET)

Journal article PEDIATRIC BLOOD & CANCER · September 1, 2013 Link to item Cite

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Journal article Cancer Immunol Res · September 2013 A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using ... Full text Link to item Cite

Biomarkers to help guide management of patients with pulmonary nodules.

Journal article Am J Respir Crit Care Med · August 15, 2013 RATIONALE: Indeterminate pulmonary nodules are a common radiographic finding and require further evaluation because of the concern for lung cancer. OBJECTIVES: We developed an algorithm to assign patients to a low- or high-risk category for lung cancer, ba ... Full text Open Access Link to item Cite

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Journal article Int J Radiat Oncol Biol Phys · August 1, 2013 PURPOSE: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. METHODS AND MATERIALS: ... Full text Link to item Cite

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Journal article J Neurooncol · August 2013 Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized th ... Full text Link to item Cite

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Journal article Cancer Immunol Immunother · June 2013 B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to e ... Full text Link to item Cite

The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.

Journal article Breast Cancer Res Treat · April 2013 We examined cardiorespiratory fitness (CRF) levels in early stage breast cancer patients and determined whether CRF differs as a function of adjuvant therapy regimen. A total of 180 early breast cancer patients representing three treatment groups (surgery ... Full text Link to item Cite

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Journal article Cancer Med · April 2013 Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblas ... Full text Open Access Link to item Cite

Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.

Journal article Psychooncology · February 2013 OBJECTIVES: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. METHODS: Sociodemographic data, including ... Full text Open Access Link to item Cite

Subarachnoid hemorrhage trials.

Journal article J Neurosurg · January 2013 Full text Link to item Cite

Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Journal article PLoS One · 2013 BACKGROUND: While curable at early stages, few treatment options exist for advanced melanoma. Currently, no consensus exists regarding the optimal surveillance strategy for patients after resection. The objectives of this study were to identify patterns of ... Full text Open Access Link to item Cite

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Journal article PLoS One · 2013 Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be ... Full text Open Access Link to item Cite

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.

Journal article Cancer Invest · November 2012 OBJECTIVES: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. METHODS: MM patients were identified from a prospectively maintained databas ... Full text Link to item Cite

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Journal article Br J Cancer · October 23, 2012 BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among rec ... Full text Open Access Link to item Cite

Clinicopathologic study of 85 cases of melanoma of the female genitalia.

Journal article J Am Acad Dermatol · October 2012 BACKGROUND: Melanoma of the female genitalia has poor overall prognosis. OBJECTIVE AND METHODS: To examine prognostic factors influencing survival, the Duke Melanoma and Tumor Registry Databases were queried for patients who had received their clinical car ... Full text Link to item Cite

Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients.

Journal article Support Care Cancer · October 2012 PURPOSE: Spiritual care is an important part of healthcare, especially when facing the crisis of advanced cancer. Do oncology inpatients receive spiritual care consistent with their needs? When inconsistent, are there deleterious effects on patient outcome ... Full text Link to item Cite

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Journal article Cancer · October 1, 2012 BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratifie ... Full text Link to item Cite

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Journal article J Neurooncol · August 2012 Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have y ... Full text Link to item Cite

Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

Journal article J Clin Oncol · July 10, 2012 PURPOSE: To evaluate cardiopulmonary function (as measured by peak oxygen consumption [VO(2peak)]) across the breast cancer continuum and its prognostic significance in women with metastatic disease. PATIENTS AND METHODS: Patients with breast cancer repres ... Full text Link to item Cite

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Journal article J Neurooncol · July 2012 To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma pat ... Full text Link to item Cite

Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.

Journal article Lung Cancer · May 2012 BACKGROUND: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Using a prospective design, 118 consecutive participants with histologic ... Full text Link to item Cite

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Journal article J Neurooncol · March 2012 We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] ... Full text Link to item Cite

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Journal article J Neurooncol · March 2012 Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a ... Full text Link to item Cite

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Journal article Cancer · March 1, 2012 BACKGROUND: The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide. METHODS: There was no limit on the ... Full text Link to item Cite

Clinical data simplified.

Journal article J Neurosurg · February 2012 Full text Link to item Cite

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Journal article Int J Radiat Oncol Biol Phys · January 1, 2012 PURPOSE: To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: A total of 125 patients with newly diagnosed GBM were enrolled in ... Full text Link to item Cite

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Journal article PLoS One · 2012 BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy ... Full text Open Access Link to item Cite

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Journal article Nucl Med Biol · January 2012 INTRODUCTION: Malignant glioma remains a significant therapeutic challenge, and immunotherapeutics might be a beneficial approach for these patients. A monoclonal antibody (MAb) specific for multiple molecular targets could expand the treatable patient pop ... Full text Link to item Cite

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Journal article J Neurooncol · January 2012 We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. A ... Full text Link to item Cite

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Journal article J Neurooncol · December 2011 We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For ea ... Full text Link to item Cite

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal article Cancer · December 1, 2011 BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received ca ... Full text Link to item Cite

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

Journal article J Neurooncol · December 2011 We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SC ... Full text Link to item Cite

DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA

Journal article NEURO-ONCOLOGY · November 1, 2011 Link to item Cite

TRUNCATED NEUROKININ 1 RECEPTOR: EXPRESSION IN PRIMARY GLIOBLASTOMAS AND RELATIONSHIP WITH PATIENT SURVIVAL

Journal article NEURO-ONCOLOGY · November 1, 2011 Link to item Cite

PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS

Journal article NEURO-ONCOLOGY · November 1, 2011 Link to item Cite

THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME

Journal article NEURO-ONCOLOGY · November 1, 2011 Link to item Cite

The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.

Journal article J Thorac Oncol · October 2011 INTRODUCTION: Lung cancers can display immune cell infiltration although the role of an adaptive immune response in disease pathogenesis is unknown. To investigate the possibility of a functional humoral response to the tumor, we surveyed histologic sectio ... Full text Link to item Cite

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Journal article Blood · September 15, 2011 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vacc ... Full text Link to item Cite

Epidemiology.

Journal article J Neurosurg · August 2011 Full text Link to item Cite

Reply to M.S. Lesniak

Journal article Journal of Clinical Oncology · August 1, 2011 Full text Cite

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Journal article J Clin Oncol · July 20, 2011 PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this populati ... Full text Link to item Cite

Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.

Journal article Int J Cancer · July 1, 2011 Glycoprotein NMB (GPNMB), a transmembrane glycoprotein highly expressed in high-grade gliomas (HGGs), is an attractive target in cancer immunotherapy. We isolated a GPNMB-specific scFv clone, G49, from a human synthetic phage-display library. To obtain mut ... Full text Link to item Cite

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Journal article Clin Cancer Res · June 15, 2011 PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective. EXPERIMENTAL DESIGN: A total of 75 patients ... Full text Link to item Cite

Reply to M.C. Chamberlain

Journal article Journal of Clinical Oncology · June 10, 2011 Full text Cite

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal article J Neurooncol · June 2011 We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received ... Full text Link to item Cite

Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.

Journal article Journal of Clinical Oncology · May 20, 2011 Full text Cite

Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.

Journal article Journal of Clinical Oncology · May 20, 2011 Full text Cite

A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).

Journal article Journal of Clinical Oncology · May 20, 2011 Full text Cite

Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.

Journal article JOURNAL OF CLINICAL ONCOLOGY · May 20, 2011 Link to item Cite

Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.

Journal article J Clin Oncol · May 20, 2011 2082 Background: Most patients with a malignant glioma recur after primary chemoradiation. Bevacizumab (BVZ) has been shown in phase II trials to improve disease-free survival in patients with recurrent glioma. Retrospective studies of stereotactic radiosu ... Link to item Cite

Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.

Journal article J Clin Oncol · May 20, 2011 2030 Background: Although BV benefits most recurrent GBM patients, the duration of benefit is limited and subsequent survival after BV progression is poor due to lack of effective therapeutic options. METHODS: We performed a meta-analysis of five consecuti ... Link to item Cite

Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.

Journal article J Clin Oncol · May 20, 2011 2055 Background: Patients with unresectable or multifocal glioblastomas (GBs) have a poor prognosis with median survival of 6-10 months. Given the angiogenic phenotype of GB, we conducted two phase II trials of upfront 5-day temozolomide (TMZ) and Bevacizu ... Link to item Cite

A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).

Journal article J Clin Oncol · May 20, 2011 2070 Background: AC480 is a novel oral tyrosine kinase inhibitor of the human epidermal growth factor receptor family, especially EGFR and HER2. EGFR is an important therapeutic target in MG. We performed a pilot study to evaluate the tumor and plasma PK o ... Link to item Cite

Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study.

Journal article Psychooncology · May 2011 OBJECTIVE: In a pilot study, participation in the Pathfinders program was associated with reductions in distress and despair and improvements in quality of life (QOL) among advanced breast cancer patients. This study explores the relationship between psych ... Full text Link to item Cite

Resection of vestibular schwannomas.

Journal article J Neurosurg · May 2011 Full text Link to item Cite

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Journal article J Natl Compr Canc Netw · April 2011 Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth fa ... Full text Link to item Cite

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Journal article Neuro Oncol · March 2011 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic c ... Full text Link to item Cite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Journal article J Neurooncol · January 2011 Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing ... Full text Link to item Cite

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Journal article Neuro Oncol · December 2010 Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination w ... Full text Link to item Cite

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Journal article J Clin Oncol · November 1, 2010 PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed ... Full text Link to item Cite

Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.

Journal article Cancer · October 15, 2010 BACKGROUND: Identifying strong markers of prognosis is critical to optimize treatment and survival outcomes in patients with nonsmall cell lung cancer (NSCLC). The authors investigated the prognostic significance of preoperative cardiorespiratory fitness ( ... Full text Link to item Cite

Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.

Journal article BMC Cancer · October 6, 2010 BACKGROUND: The Exercise Intensity Trial (EXcITe) is a randomized trial to compare the efficacy of supervised moderate-intensity aerobic training to moderate to high-intensity aerobic training, relative to attention control, on aerobic capacity, physiologi ... Full text Open Access Link to item Cite

Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.

Journal article Neurol Res · October 2010 OBJECTIVES: While convection enhanced delivery (CED) is an effective delivery method that bypasses the blood-brain barrier, its utility is limited by infusate leakage due to catheter misplacement. Therefore, it is critical to evaluate drug distribution dur ... Full text Link to item Cite

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

Journal article J Pain Symptom Manage · October 2010 CONTEXT: The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has n ... Full text Link to item Cite

Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.

Journal article Lancet · September 4, 2010 BACKGROUND: Palliative oxygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who are ineligible for long-term oxygen therapy. We assessed the effectiveness of oxygen compared with room air delivered by nasal cann ... Full text Link to item Cite

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Journal article BMC Cancer · September 1, 2010 BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular th ... Full text Open Access Link to item Cite

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Journal article J Neurosurg · August 2010 OBJECT: Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet cl ... Full text Link to item Cite

Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians.

Journal article Am J Hematol · July 2010 Full text Link to item Cite

Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.

Journal article Support Care Cancer · July 2010 PURPOSE: Pathfinders is a multi-faceted psychosocial care program for cancer patients; it was developed in community oncology and adapted to the academic oncology setting. This prospective, single-arm, phase 2 pilot study examined the acceptability and fea ... Full text Link to item Cite